Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Xigris

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The sepsis biologic will be reviewed by FDA's Anti-Infective Drugs Advisory Committee Sept. 12. Drotrecogin alfa initially was to be reviewed July 17, but the meeting was delayed when the agency extended the user fee date for the product from July 27 to Oct. 27 to allow more time for evaluation. Lilly has entered an agreement with Syncor for an "emergency response delivery service" for Xigris that would supply the product to most hospitals within three hours

You may also be interested in...



UK Biotech Financing Holds Up Despite Woodford and Brexit

Neil Woodford’s fall from grace and Brexit dragged on an otherwise buoyant sector

Glenmark Sells Gynecology Unit

Glenmark has struck a deal with private equity firm True North for its gynecology business in India and Nepal.

Alembic Aims To Build On Booming US Business

With its predominantly solid-dose portfolio in the US producing strong growth, India’s Alembic Pharmaceuticals is increasingly securing FDA clearance to push into differentiated dosage forms.

Topics

UsernamePublicRestriction

Register

PS001573

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel